(Total Views: 450)
Posted On: 08/19/2019 1:30:11 PM
Post# of 154851
The good Doc is getting a lot of responses pointing him to Cytodyn.
He did not respond after his classical “why the low marketcap” not even on your -and others- explanation.
While he did respond to others.
Maybe he’s busy studying Cydy now and wants to give an opinionated response.
It is somewhat strange though that in a company analysis not all competing companies in phase 3 HIV trials are taken into account.
It’s not so hard to find out who are of have completed phase 3 trials.
Cydy is really unknown (or unwanted?).
I’ve added a comment to the SA article too. The more the merrier!
He did not respond after his classical “why the low marketcap” not even on your -and others- explanation.
While he did respond to others.
Maybe he’s busy studying Cydy now and wants to give an opinionated response.
It is somewhat strange though that in a company analysis not all competing companies in phase 3 HIV trials are taken into account.
It’s not so hard to find out who are of have completed phase 3 trials.
Cydy is really unknown (or unwanted?).
I’ve added a comment to the SA article too. The more the merrier!
(2)
(0)
